Drug intelligence / Profile preview

PEVArx

Development stage: Preclinical
Lead developer: Aytu BioPharma
Modality: Small Molecules
Administration: Oral

Overview

**PEVArx** is an oral, multi-ingredient nutritional supplement developed by Innovus Pharmaceuticals for sexual-performance support, including delayed ejaculation and premature ejaculation. The formulation includes vitamin B6, magnesium, four amino acids, and the absorption-enhancing ingredients AstraGin and BioPerine. Innovus-sponsored patent materials describe improvements in sexual-intercourse duration, satisfaction, and erectile-function measures in a placebo-controlled pilot study; however, PEVArx was marketed as a dietary supplement rather than as an FDA-approved pharmaceutical treatment. ([pdf.manuals.plus](https://pdf.manuals.plus/m/857f70a8b7890a144dbe4d7ee6ff2cd3bfca67495434c334de6794ce7074a109.pdf))

Brand names: PEVArx
Other names: PEVarx

Beyond the preview

Go deeper on PEVArx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEVArx.

Explore the full profile